Stockreport

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results

Landos Biopharma, Inc.  (LABP) 
PDF Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into mid [Read more]